XyloCor Therapeutics, Inc.
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
XyloCor Therapeutics, Inc.
This company focuses on gene therapy for advanced coronary artery disease, aiming to improve the lives of people with cardiovascular disease.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Advanced gene therapy solutions
Tools for clinical trial data management and analysis.
Scalable manufacturing processes for gene therapy products.
Service Requirements
Regulatory consulting for gene therapy product approval.
Clinical trial management services.
Expertise in cardiovascular disease treatment protocols.
Infrastructure Requirements
Specialized facilities for gene therapy research and development.
Secure data storage and processing for sensitive patient data.
Compliance infrastructure to meet regulatory requirements for gene therapy products.
Talent Requirements
Gene therapy scientists and researchers.
Clinical trial specialists with expertise in cardiovascular disease.
Regulatory affairs professionals experienced in gene therapy product approvals.
AI Insights
Growth Trajectory
The company's growth potential is strong, evidenced by the recent $67.5 million Series B funding, which signals a significant push towards clinical development and market entry.
Market Opportunity
The company has a significant market opportunity in addressing the unmet clinical needs in cardiovascular disease with its proprietary gene therapy technologies.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats